Good morning, everyone, and how are you today? We are doing quite nicely, thank you, helped by an unexpectedly quiet Pharmalot campus, which is benefiting from a shiny sun and deliciously cool breeze. May is a delightful month, yes? Nonetheless, we can stare out the window just so long. After all, there is much to do. So, time to get cracking. Here are some tidbits to help you on your own journey today. Hope all goes well and, as always, do keep in touch. We enjoy your thoughts. …

Takeda (TAK) Pharmaceutical (TKPHF), which is looking to pay down debt following its megadeal for Shire, is selling the Xiidra eye drug to Novartis (NVS) (NVS) and the TachoSil surgical patches and sealants to the Johnson & Johnson (JNJ) Ethicon unit, The Wall Street Journal notes. The deals, expected to close in the second half of the year, would bring Takeda $3.8 billion in cash up front and up to $1.9 billion in additional payments from Novartis subject to certain milestones being met. Takeda has said it would sell about $10 billion worth of assets to pay down debt.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy